Serum protein 90K/Mac-2BP is an independent predictor of disease severity during hepatitis C virus infection

Clinical Chemistry and Laboratory Medicine

Volumn 38, Issue 3, 2000, Pages 205-208

  Kittl, Eva M ^a   Hofmann, Jörg ^a   Hartmann, Gerold ^b   Sebesta, Christian ^b   Beer, Franz ^b   Bauer, Kurt ^a   Huber, Klaus R ^a  

^a LUDWIG BOLTZMANN INSTITUTE FOR LUNG VASCULAR RESEARCH   (Austria)

^b DANUBE HOSPITAL   (Austria)

Author keywords

90K Mac 2BP; HCV genotypes; Liver function tests; Viral load

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; CHOLINESTERASE; GAMMA GLUTAMYLTRANSFERASE; PLASMA PROTEIN; TETRAMETHYLBENZIDINE;

ADOLESCENT; ADULT; AGE; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CHOLINESTERASE BLOOD LEVEL; DEVICE; DIAGNOSTIC VALUE; DISEASE SEVERITY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GAMMA GLUTAMYL TRANSFERASE BLOOD LEVEL; HEPATITIS C; HUMAN; MAJOR CLINICAL STUDY; MALE; PREDICTION; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; VIRUS LOAD;

HEPATITIS C VIRUS; RNA VIRUSES;

EID: 0034124789     PISSN: 14346621     EISSN: None     Source Type: Journal    
DOI: 10.1515/CCLM.2000.029     Document Type: Article

References (16)

1. Chemello L, Bonetti B, Cavalletto L, Talavato F, Donadon V, Casarin P, et al. Randomized trial comparing three different regimens of alpha-2a-interferon in chronic hepatitis C. Hepatology 1995; 22:700-6.
2. Lin R, Roach E, Zimmermann M, Strasser S, Farrell G. Interferon alpha-2b for chronic hepatitis C: effects of dose increment and duration of treatment on response rates. J Hepatol 1995; 23:487-96.
3. Huber KR, Sebesta C, Worofka B, Kittl E, Hofmann J, Klar S, et al. Diagnostic challenges of hepatitis C virus infection. Drugs of Today 1998; 34:11-5.
4. Inohara H, Akahani S, Koths K, Raz A. Interactions between galectin-3 and Mac 2-binding protein mediate cell-cell adhesion. Cancer-Res. 1996; 56:4530-4.
5. Artini M, Natoli C, Tinari N, Costanzo A, Marinelli R, Balsano C, et al. Elevated serum levels of 90K/Mac-2BP predict unresponsiveness to α-interferon therapy in chronic HCV hepatitis patients. J Hepatol 1996; 25:212-7.
6. Huber KR, Sebesta C, Bauer K. Detection of common hepatitis C virus subtypes with a third-generation enzyme immunoassay. Hepatology 1996; 24:471-3.
7. Huber KR, Knapp M, Bauer K. Subtyping hepatitis C virus. Clin Chem 1995; 41:319-20.
8. Bender MedSystems. 90K/Mac-2BP ELISA: product information and manual. Boehringer Ingelheim Bioproducts, Czernyring 22/11, D-69115 Heidelberg.
9. Linsley PS, Horn D, Marquardt H, Brown JP, Hellstrom I, Hellstrom KE, et al. Identification of a novel serum protein secreted by lung carcinoma cells. Biochem 1986; 25:2978-86.
10. Iacobelli S, Arno E, D'Orazio A, Coletti G. Detection of antigens recognized by a novel monoclonal antibody in tissue and serum from patients with breast cancer. Cancer Res 1986; 46:3005-10.
11. Iacobelli S, Arno E, Sismondi P, Natoli C, Gentiloni N, Scambia G, et al. Measurement of a breast cancer associated antigen detected by monoclonal antibody (SP-2) in sera of cancer patients. Breast Cancer Res Treat 1988; 11:19-30.
12. Iacobelli S, Bucci I, D'Egidio M, Giuliani C, Natoli C, Tinari N, et al. Purification and characterization of a 90 kDa protein released from human tumors and tumor cell lines. FEBS Lett 1993; 319:59-65.
13. Ullrich A, Sures I, D'Egidio M, Jallal B, Powell T, Herbst R, et al. The secreted tumor-associated antigen 90K/Mac-2BP is a potent immune stimulator. J Biol Chem 1994; 269;18401-7.
14. Koths K, Taylor E, Halenbeck R, Casipit C, Wang A. Cloning and characterization of a human Mac-2-binding protein, a new member of the superfamily defined by the macrophage scavenger receptor cysteine-rich domain. J Biol Chem 1993; 268:14245-9.
15. Rosenberg I, Cherayil BJ, Isselbacher KJ, Pillai S. Mac-2-binding glycoproteins. Putative ligands for a cytosolic beta-galactoside lectin. J Biol Chem 1991; 266:18731-6.
16. Powell TJ, Schreck R, McCall M, Hui T, Rice A, App H, et al. A tumor-derived protein which provides T-cell costimulation through accessory cell activation. J Immunother Emphasis Tumor Immunol 1995; 17:209-21.